AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery

AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery PR Newswire

* Multi-year partnership applies Iambic's AI platform to speed up small molecule drug discovery in immunology, neuroscience and oncology * Companies to pursue programs with both first-in-class and best-in-class potential, combining Iambic's molecular superintelligence platform with AbbVie's therapeutic area expertise NORTH CHICAGO, Ill. and SAN DIEGO, Sept. 21, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Iambic, a clinical-stage life sciences and technology company developing novel medicines through its AI-driven discovery and development platform, today announced a multi-year collaboration to accelerate the discovery and development of small molecule therapies with first-in-class and best-in-class potential across immunology, neuroscience and oncology. The companies will leverage Iambic's AI platform to improve the efficiency and success of identifying promising new drug candidates.